Global Startups Insights
Lets your startup
California, Funding News, USA Startup Funding News

Tempo Therapeutics Raises $14.5 Million in Financing to Advance Regenerative Medicine Technology

September 18, 2026
By
Olivia Smith
Tempo Therapeutics Raises $14.5 Million in Financing to Advance Regenerative Medicine Technology

Tempo Therapeutics, a clinical-stage regenerative medicine company, has raised $14.5 million in an oversubscribed financing round led by Galaxy Sirius Partners.

The round also includes participation from Johnson & Johnson Innovation – JJDC, Inc., along with Gideon Strategic Partners, Mesa Verde Venture Partners, YK Bioventures, and other new and existing investors.

Funding to Support MAP™ Technology

Tempo will use the new funding to advance its lead surgical reconstruction program toward potential FDA clearance and commercialization.

The company will also use part of the funding to generate clinical data for additional applications of its Microporous Annealed Particle (MAP™) technology, including potential uses in aesthetic dermatology.

Clinical Results

Tempo recently published results from its first-in-human clinical study involving 40 patients with full-thickness wounds following Mohs surgery for non-melanoma skin cancer.

The randomized, controlled study met its primary safety endpoint, with no serious adverse device effects, infections, or delayed wound healing reported with MAP treatment.

MAP-treated wounds reached a favorable wound-bed score approximately 14 days earlier than the control group. After around six months, MAP-treated wounds also showed improved physician-assessed scar quality compared with standard hydrocolloid treatment.

About MAP™ Technology

MAP is a fully synthetic, flowable, porous biomaterial designed to support cellular infiltration, blood vessel formation, and new tissue development.

Tempo is initially developing the technology for surgical reconstruction and wound healing, where it is designed to provide a temporary scaffold that supports the body’s natural regenerative processes.

The company is also exploring potential applications in regenerative aesthetics, including tissue changes associated with weight loss and healthy aging.

Leadership Changes

Following the financing, Eric Richman has been appointed Interim CEO, while Steven Sands, Co-Principal of Galaxy Sirius Partners, has become Chairman of the Board.

Tempo Co-Founder Westbrook Weaver, Ph.D., will serve as Chief Technology Officer, while Don Griffin, Ph.D., will serve as Chief Scientific Officer and a member of the Board.

Tempo’s lead product has completed first-in-human clinical evaluation and has been submitted to the U.S. FDA through the De Novo pathway.

Recommended Stories for You